DK0708771T3 - Benzyloxyquinuclidiner som substans P antagonister - Google Patents
Benzyloxyquinuclidiner som substans P antagonisterInfo
- Publication number
- DK0708771T3 DK0708771T3 DK94919851T DK94919851T DK0708771T3 DK 0708771 T3 DK0708771 T3 DK 0708771T3 DK 94919851 T DK94919851 T DK 94919851T DK 94919851 T DK94919851 T DK 94919851T DK 0708771 T3 DK0708771 T3 DK 0708771T3
- Authority
- DK
- Denmark
- Prior art keywords
- pct
- c6alkyl
- c6alkoxy
- sec
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17560993 | 1993-07-15 | ||
PCT/JP1994/001092 WO1995002595A1 (en) | 1993-07-15 | 1994-07-05 | Benzyloxyquinuclidines as substance p antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0708771T3 true DK0708771T3 (da) | 1999-06-21 |
Family
ID=15999090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94919851T DK0708771T3 (da) | 1993-07-15 | 1994-07-05 | Benzyloxyquinuclidiner som substans P antagonister |
Country Status (10)
Country | Link |
---|---|
US (1) | US5869499A (da) |
EP (1) | EP0708771B1 (da) |
JP (1) | JP2843921B2 (da) |
AT (1) | ATE171945T1 (da) |
CA (1) | CA2167198C (da) |
DE (1) | DE69413822T2 (da) |
DK (1) | DK0708771T3 (da) |
ES (1) | ES2121213T3 (da) |
FI (1) | FI960156A0 (da) |
WO (1) | WO1995002595A1 (da) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9706944A (es) * | 1996-09-12 | 1998-08-30 | Pfizer | Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p. |
WO1998033379A1 (en) * | 1997-02-04 | 1998-08-06 | The General Hospital Corporation | A novel method for treating epidermal or dermal conditions |
AU736510B2 (en) * | 1997-06-27 | 2001-07-26 | Nippon Kayaku Kabushiki Kaisha | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives |
US20040142929A1 (en) * | 2001-07-06 | 2004-07-22 | Ramon Merce-Vidal | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence |
US20060205724A1 (en) * | 2002-05-29 | 2006-09-14 | The Regents Of The University Of California | Antagonizing nk-1 receptors inhibits consumption of substances of abuse |
BRPI0513359A (pt) | 2004-07-15 | 2008-05-06 | Amr Technology Inc | tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina |
EP1888050B1 (en) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer |
NZ565111A (en) | 2005-07-15 | 2011-10-28 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
EP3103791B1 (en) | 2007-06-27 | 2018-01-31 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
WO2009111354A2 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
AU2010247763B2 (en) | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
KR20120023072A (ko) | 2009-05-12 | 2012-03-12 | 브리스톨-마이어스 스큅 컴퍼니 | (S)-7-(〔1,2,4〕트리아졸〔1,5-a〕피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도 |
US8375635B2 (en) * | 2009-08-26 | 2013-02-19 | Richard Hellinga | Apparatus for opening and closing overhead sectional doors |
CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
JP6043285B2 (ja) | 2010-08-02 | 2016-12-14 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | 低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害 |
EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
EP3327125B1 (en) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
CA2833009A1 (en) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Insulin-like growth factor-1 receptor inhibitors |
WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
RS56680B1 (sr) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Kompozicije i postupci za lečenje kancera |
MX2015008196A (es) | 2012-12-20 | 2015-09-16 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana. |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
US5631281A (en) * | 1989-06-29 | 1997-05-20 | Warner-Lambert Company | N-substituted cycloalkyl and polycycloalkyl α-substituted Trp-Phe- and phenethylamine derivatives |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
JP2807577B2 (ja) * | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
DE69220258T2 (de) * | 1991-02-11 | 1997-12-18 | Merck Sharp & Dohme | Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung |
DE69214333T2 (de) * | 1991-03-22 | 1997-04-24 | Merck & Co Inc | Arzneizubereitung mit hohem Gehalt an Ibuprofenlysinat |
US5620971A (en) * | 1991-05-09 | 1997-04-15 | Vertex Pharmaceuticals Incorporated | Biologically active acylated amino acid derivatives |
DE69232334T2 (de) * | 1991-05-22 | 2002-11-14 | Pfizer | Substituierte 3-aminochinuclidine |
WO1993013083A1 (en) * | 1991-12-31 | 1993-07-08 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
JP2656702B2 (ja) * | 1992-03-23 | 1997-09-24 | ファイザー製薬株式会社 | ペプチド性キヌクリジン |
TW270927B (da) * | 1992-10-16 | 1996-02-21 | Otsuka Pharma Co Ltd | |
US5620989A (en) * | 1992-10-28 | 1997-04-15 | Merck Sharp & Dohme Limited | 4-Arylmethyloxymethyl piperidines as tachykinin antagonsits |
JP2656700B2 (ja) * | 1992-10-28 | 1997-09-24 | ファイザー製薬株式会社 | 置換キヌクリジン誘導体 |
JPH06149350A (ja) * | 1992-10-30 | 1994-05-27 | Johnson Kk | 自走車の誘導システム |
IT1256450B (it) * | 1992-11-26 | 1995-12-05 | Soldato Piero Del | Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione |
US5622950A (en) * | 1993-03-01 | 1997-04-22 | Merck, Sharp & Dohme Ltd. | Pyrrolo-pyridine derivatives |
US5607946A (en) * | 1993-03-05 | 1997-03-04 | Merck Sharp & Dohme Ltd. | Quinolone derivatives as dopamine D4 ligands |
US5622980A (en) * | 1993-08-17 | 1997-04-22 | Applied Analytical Industries, Inc. | Oral compositions of H2-antagonists |
GB9409882D0 (en) * | 1994-05-18 | 1994-07-06 | Sandoz Ltd | Organic compounds |
US5621004A (en) * | 1994-06-03 | 1997-04-15 | Robert W. Dunn | Method for treating emesis |
GB9413090D0 (en) * | 1994-06-29 | 1994-08-17 | Merck Sharp | Benzazepine derivatives compositions containing them and their use in therapy |
US5621140A (en) * | 1994-12-22 | 1997-04-15 | Syntex (U.S.A.) Inc. | Resolution of ibuprofen |
US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
-
1994
- 1994-07-05 DK DK94919851T patent/DK0708771T3/da active
- 1994-07-05 WO PCT/JP1994/001092 patent/WO1995002595A1/en active IP Right Grant
- 1994-07-05 JP JP7504461A patent/JP2843921B2/ja not_active Expired - Fee Related
- 1994-07-05 ES ES94919851T patent/ES2121213T3/es not_active Expired - Lifetime
- 1994-07-05 AT AT94919851T patent/ATE171945T1/de not_active IP Right Cessation
- 1994-07-05 EP EP94919851A patent/EP0708771B1/en not_active Expired - Lifetime
- 1994-07-05 US US08/637,682 patent/US5869499A/en not_active Expired - Fee Related
- 1994-07-05 DE DE69413822T patent/DE69413822T2/de not_active Expired - Fee Related
- 1994-07-05 CA CA002167198A patent/CA2167198C/en not_active Expired - Fee Related
-
1996
- 1996-01-12 FI FI960156A patent/FI960156A0/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2843921B2 (ja) | 1999-01-06 |
FI960156A (fi) | 1996-01-12 |
WO1995002595A1 (en) | 1995-01-26 |
EP0708771A1 (en) | 1996-05-01 |
EP0708771B1 (en) | 1998-10-07 |
JPH08511028A (ja) | 1996-11-19 |
DE69413822T2 (de) | 1999-02-25 |
ATE171945T1 (de) | 1998-10-15 |
ES2121213T3 (es) | 1998-11-16 |
US5869499A (en) | 1999-02-09 |
FI960156A0 (fi) | 1996-01-12 |
CA2167198C (en) | 1999-03-16 |
CA2167198A1 (en) | 1995-01-26 |
DE69413822D1 (de) | 1998-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0708771T3 (da) | Benzyloxyquinuclidiner som substans P antagonister | |
DE60127595T2 (de) | Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen | |
BR0212468A (pt) | Compoto de uréia ativos como antagonistas de receptor de vanilóides para o tratamento de dor | |
DK0665843T3 (da) | Substituerede quinuclidiner som substans P-antagonister | |
FI935134A0 (fi) | Substituerade 3-aminokinuklidiner | |
SE9902987D0 (sv) | Novel compounds | |
DK0668863T3 (da) | Quinuclidinderivat som substans P-antagonist | |
DE69840510D1 (de) | Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung | |
DE69429591T2 (de) | Therapeutisch wirksame Verbindungen | |
EE03262B1 (et) | Imidaso[1,2-a]püridiinidest saadavad alkoksüalküülkarbamaadid, nende valmistamine ja kasutamine | |
ATE269865T1 (de) | Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren | |
SE9804212D0 (sv) | Compounds | |
GB0104050D0 (en) | Chemical compounds | |
BR9503572A (pt) | Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença | |
DE69500673T2 (de) | Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind | |
ATE370147T1 (de) | Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors | |
NO20044531L (no) | Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom | |
BR9611276A (pt) | Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto | |
BR0212077A (pt) | Compostos de aminopirróis como agentes antiinflamatórios | |
SE9202218D0 (sv) | Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation | |
SE0302666D0 (sv) | Novel Compounds | |
BR0116724A (pt) | Composto, método de tratamento de um distúrbio neurológico ou de uma doença neurodegenerativa, método de tratamento de dor, composição farmacêutica, uso de um composto, e, processos para a preparação e para a sìntese de um composto |